Timber Pharmaceuticals

Today we entered into a definitive agreement to be acquired by LEO Pharma @LEOHealthySkin, a wholly-owned subsidiary of LEO Pharma A/S. The transaction is expected to close in the fourth quarter of 2023 subject to closing conditions. See our press release: timberpharma.com/news-releases

Today we shared interim pharmacokinetic analyses from the Phase 3 ASCEND study, our pivotal clinical trial for moderate to severe X-linked (RXLI) or lamellar #ichthyosis (ARCI). We plan to present the data at #SPD2023 in July. Find details: timberpharma.com/news-releases

Peyton lives with X-linked #ichthyosis, characterized by dry, scaly patches of skin that cover the body. “When I’m not itching, I just feel different. I feel better, because I’m not constantly scratching.” Read more from @FIRST_Skin: firstskinfoundation.org/news/yale-is-t…

We’re grateful for the support of @YaleMed, which has been an integral part of our congenital #ichthyosis development program as the only U.S. site involved in all 3 of our clinical trials. Dr. Chris Bunick talks more about the study in @DermTimes: dermatologytimes.com/view/tmb-001-f…

As we recognize the end of #IchthyosisAwarenessMonth, we encourage you to visit @FIRST_Skin to learn more about congenital #ichthyosis and its impact on patients and families: firstskinfoundation.org

After developing itchy, painful scales on his skin, Aditya was diagnosed with congenital #ichthyosis (CI) at seven years old. Now, he’s sharing his story to build awareness of this rare genetic skin condition and help others feel less alone. Read more: scarysymptoms.com/2022/09/medica…

Learn more about the ASCEND study, a randomized controlled pivotal Phase 3 clinical trial in patients with autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI) or X-linked recessive #ichthyosis (XRI). Learn more at ichthyosistrial.com

May 20 marks #ClinicalTrialsDay. As we continue to advance our pivotal Phase 3 ASCEND study for congenital #ichthyosis, we thank the site investigators, research staff, patients, caregivers and families who have helped us move this important research effort forward.

Earlier this year, @DermTimes included details of a sub-analysis of the Phase 2B CONTROL study that was recently published online in Clinical and Experimental Dermatology. Read now: dermatologytimes.com/view/new-tmb-0…

Peyton Fleagle was just a toddler when his parents first noticed itchy scales on his skin. Eventually the scales covered 95% of Peyton's body. @Medical_xpress shares more about our work on behalf of Peyton & all those living with congenital #ichthyosis: medicalxpress.com/news/2023-02-d…

Thanks to Dr. Joyce Teng of Stanford University School of Medicine, for contributing her perspectives to a @Healio article covering an analysis of our Phase IIb CONTROL study for congenital #ichthyosis. Read now: healio.com/news/dermatolo…

May is #Ichthyosis Awareness Month, an opportunity to join with patients & families around the world to raise awareness about the challenges & hopes of the ichthyosis community. Learn how you can get involved: firstskinfoundation.org/ichthyosis-awa… #IAM23 @FIRST_Skin

Today we announced the online publication of a sub-analysis of the Phase 2B CONTROL study in Clinical and Experimental Dermatology (CED), the educational journal of the British Association of Dermatologists (@HealthySkin4All). See our press release: timberpharma.com/news-releases

We’re grateful to work with patient advocates who are passionate about sharing their stories with their communities to raise awareness of congenital #ichthyosis & opportunities to participate in clinical research. The Fleagle family shares their story: patch.com/connecticut/en…

The @AADskin Annual Meeting begins today! #AAD2023 will discuss some of the most important topics and latest updates in #dermatology and provide the opportunity to connect with more than 8k members of the clinical and research community. View here: aad.org/member/meeting…

#ICYMI Last month, we received orphan drug designation for our lead candidate in development for the treatment of X-linked recessive #ichthyosis (XLRI) from the European Commission. Learn more: timberpharma.com/news-releases

In an interview with @AuthorityMag, Christina and Peyton share their experiences with X-linked #ichthyosis in an effort to build awareness of this rare genetic skin disorder: medium.com/authority-maga…

Aditya was recently interviewed as part of @AuthorityMag’s #Unstoppable series, where he shared his story & talked about his work as a patient advocate and desire to help others living with congenital #ichthyosis. Read now: medium.com/authority-maga…

Thank you to the Fleagle family & Dr. Christopher Bunick of @yalederm for creating greater awareness of congenital #ichthyosis and the work we are doing, together, to help patients in need. Read now: news.yale.edu/2023/02/09/yal…

Today we recognize #RareDiseaseDay and show our support for the 300+ million individuals impacted by #rarediseases worldwide, including #ichthyosis. Join us today in celebrating #RDD2023 with @First_Skin: firstskinfoundation.org/news/rare-dise…